Tags

Type your tag names separated by a space and hit enter

Symptoms, Management and Healthcare Utilization of COPD Patients During the COVID-19 Epidemic in Beijing.
Int J Chron Obstruct Pulmon Dis. 2020; 15:2487-2494.IJ

Abstract

Background

Social distancing and restriction measures during the COVID-19 epidemic may have impacts on medication availability and healthcare utilization for COPD patients, and thereby affect standard disease management. We aimed to investigate the change of respiratory symptoms, pharmacological treatment and healthcare utilization of COPD patients during the epidemic in Beijing, China.

Methods

We conducted a single-center, cross-sectional survey performed at Peking University Third Hospital and recruited patients with COPD who were interviewed by phone call. Clinical data, including respiratory symptoms, pharmacological treatment, management and healthcare access before and during the COVID-19 epidemic from January 25 to April 25, 2020, were collected.

Results

A total of 153 patients were enrolled for analysis. Before the epidemic, 81.7% (125/153) had long-term maintenance medication and ICS/LABA (60.8%) and LAMA (57.5%) were most commonly used. During the epidemic, 75.2% (115/153) maintained their pharmacological treatment and 6.5% (10/153) had to reduce or stop taking medications, with a slight decrease of patients taking ICS/LABA (53.6%) and LAMA (56.9%). Most of the patients [76.5% (117/153)] had a low symptom burden, with a CAT score <10 during the epidemic. Of 153 patients, 45 (29.4%) patients reported worsening of respiratory symptoms but only 15.6% (7/45) sought medical care in hospitals, while the remaining expressed concerns about cross-infection in the hospital (55.5%, 25/45) or had mild symptoms which were managed by themselves (28.8%, 13/45).

Conclusion

During the COVID-19 epidemic in Beijing, most of our COPD patients maintained their long-term pharmacological treatment and had mild-to-moderate symptoms. Approximately, 30.0% of the patients experienced worsening of respiratory symptoms, but most of them did not seek medical care in the hospital due to concerns about cross-infection.

Authors+Show Affiliations

Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, 100191, People's Republic of China.Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, 100191, People's Republic of China.Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, 100191, People's Republic of China.Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, 100191, People's Republic of China.Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, 100191, People's Republic of China.Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, 100191, People's Republic of China.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33116465

Citation

Liang, Ying, et al. "Symptoms, Management and Healthcare Utilization of COPD Patients During the COVID-19 Epidemic in Beijing." International Journal of Chronic Obstructive Pulmonary Disease, vol. 15, 2020, pp. 2487-2494.
Liang Y, Chang C, Chen Y, et al. Symptoms, Management and Healthcare Utilization of COPD Patients During the COVID-19 Epidemic in Beijing. Int J Chron Obstruct Pulmon Dis. 2020;15:2487-2494.
Liang, Y., Chang, C., Chen, Y., Dong, F., Zhang, L., & Sun, Y. (2020). Symptoms, Management and Healthcare Utilization of COPD Patients During the COVID-19 Epidemic in Beijing. International Journal of Chronic Obstructive Pulmonary Disease, 15, 2487-2494. https://doi.org/10.2147/COPD.S270448
Liang Y, et al. Symptoms, Management and Healthcare Utilization of COPD Patients During the COVID-19 Epidemic in Beijing. Int J Chron Obstruct Pulmon Dis. 2020;15:2487-2494. PubMed PMID: 33116465.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Symptoms, Management and Healthcare Utilization of COPD Patients During the COVID-19 Epidemic in Beijing. AU - Liang,Ying, AU - Chang,Chun, AU - Chen,Yahong, AU - Dong,Fawu, AU - Zhang,Linlin, AU - Sun,Yongchang, Y1 - 2020/10/14/ PY - 2020/07/02/received PY - 2020/09/23/accepted PY - 2020/10/29/entrez PY - 2020/10/30/pubmed PY - 2020/11/5/medline KW - COVID-19 KW - chronic obstructive pulmonary disease KW - exacerbation KW - management SP - 2487 EP - 2494 JF - International journal of chronic obstructive pulmonary disease JO - Int J Chron Obstruct Pulmon Dis VL - 15 N2 - Background: Social distancing and restriction measures during the COVID-19 epidemic may have impacts on medication availability and healthcare utilization for COPD patients, and thereby affect standard disease management. We aimed to investigate the change of respiratory symptoms, pharmacological treatment and healthcare utilization of COPD patients during the epidemic in Beijing, China. Methods: We conducted a single-center, cross-sectional survey performed at Peking University Third Hospital and recruited patients with COPD who were interviewed by phone call. Clinical data, including respiratory symptoms, pharmacological treatment, management and healthcare access before and during the COVID-19 epidemic from January 25 to April 25, 2020, were collected. Results: A total of 153 patients were enrolled for analysis. Before the epidemic, 81.7% (125/153) had long-term maintenance medication and ICS/LABA (60.8%) and LAMA (57.5%) were most commonly used. During the epidemic, 75.2% (115/153) maintained their pharmacological treatment and 6.5% (10/153) had to reduce or stop taking medications, with a slight decrease of patients taking ICS/LABA (53.6%) and LAMA (56.9%). Most of the patients [76.5% (117/153)] had a low symptom burden, with a CAT score <10 during the epidemic. Of 153 patients, 45 (29.4%) patients reported worsening of respiratory symptoms but only 15.6% (7/45) sought medical care in hospitals, while the remaining expressed concerns about cross-infection in the hospital (55.5%, 25/45) or had mild symptoms which were managed by themselves (28.8%, 13/45). Conclusion: During the COVID-19 epidemic in Beijing, most of our COPD patients maintained their long-term pharmacological treatment and had mild-to-moderate symptoms. Approximately, 30.0% of the patients experienced worsening of respiratory symptoms, but most of them did not seek medical care in the hospital due to concerns about cross-infection. SN - 1178-2005 UR - https://www.unboundmedicine.com/medline/citation/33116465/Symptoms_Management_and_Healthcare_Utilization_of_COPD_Patients_During_the_COVID_19_Epidemic_in_Beijing_ DB - PRIME DP - Unbound Medicine ER -